Compare PBA & GEHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PBA | GEHC |
|---|---|---|
| Founded | 1997 | 1892 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Computer Software: Prepackaged Software |
| Sector | Energy | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.0B | 29.1B |
| IPO Year | 2012 | 2022 |
| Metric | PBA | GEHC |
|---|---|---|
| Price | $50.32 | $71.49 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 21 |
| Target Price | N/A | ★ $82.70 |
| AVG Volume (30 Days) | 807.7K | ★ 3.1M |
| Earning Date | 11-05-2026 | 10-28-2026 |
| Dividend Yield | ★ 4.23% | 0.22% |
| EPS Growth | N/A | ★ 4.84 |
| EPS | N/A | ★ 0.85 |
| Revenue | N/A | ★ $20,625,000,000.00 |
| Revenue This Year | $11.43 | $5.32 |
| Revenue Next Year | $2.52 | $4.60 |
| P/E Ratio | ★ $21.43 | $83.79 |
| Revenue Growth | N/A | ★ 4.84 |
| 52 Week Low | $36.20 | $58.75 |
| 52 Week High | $51.58 | $89.77 |
| Indicator | PBA | GEHC |
|---|---|---|
| Relative Strength Index (RSI) | 64.17 | 64.80 |
| Support Level | $47.48 | $68.88 |
| Resistance Level | $51.58 | $72.77 |
| Average True Range (ATR) | 1.03 | 1.71 |
| MACD | 0.39 | 0.59 |
| Stochastic Oscillator | 90.30 | 97.19 |
Pembina Pipeline is a midstream company serving the Canadian and North American (primarily Bakken) markets with an integrated product portfolio. Its operations include transmission pipelines, oil and gas gathering, fractionation, storage, and natural gas liquid exports. It also has a joint venture through the Cedar LNG export terminal.
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (15%), and pharmaceutical diagnostics (14%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 11%, and 17%, respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one-third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).